Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

(2020) John Mascarenhas et al.   BLOOD

A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia

(2020) Aaron T. Gerds et al.   BLOOD

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

(2019) Claire N Harrison et al.   BLOOD

Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naïve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib

(2019) Ruben A Mesa et al.   BLOOD

MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis

(2018) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis

(2018) Ayalew Tefferi et al.   LEUKEMIA

Momelotinib therapy for myelofibrosis: a 7-year follow-up

(2018) Ayalew Tefferi et al.   Blood Cancer Journal

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

(2018) Claire N Harrison et al.   Lancet Haematology

Classification and Personalized Prognosis in Myeloproliferative Neoplasms

(2018) Jacob Grinfeld et al.   NEW ENGLAND JOURNAL OF MEDICINE

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

(2017) Ruben A. Mesa et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment

(2017) Yan Xin et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis

(2017) A Pardanani et al.   LEUKEMIA

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

(2017) F Passamonti et al.   LEUKEMIA

Anemia in myelofibrosis—prevalence, the U2AF1 connection, new treatments

(2017) Ayalew Tefferi   Blood Cancer Journal

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

(2016) A Tefferi et al.   LEUKEMIA

Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results

(2015) Francisco Cervantes et al.   ANNALS OF HEMATOLOGY

How common are myeloproliferative neoplasms? A systematic review and meta-analysis

(2014) Glen J. Titmarsh et al.   AMERICAN JOURNAL OF HEMATOLOGY

Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis

(2013) Animesh Pardanani et al.   AMERICAN JOURNAL OF HEMATOLOGY

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

(2013) A Pardanani et al.   LEUKEMIA

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience

(2012) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens

(2010) Prakash Thapaliya et al.   AMERICAN JOURNAL OF HEMATOLOGY

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

(2010) J. W. Tyner et al.   BLOOD

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

(2009) F. Passamonti et al.   BLOOD

Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis

(2009) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD